The board meeting for Alnylam Pharmaceuticals Inc is scheduled for today, for the purpose of Morgan Stanley 23rd Annual Global Healthcare ConferenceSee details
Alnylam Pharmaceuticals Inc has a share price target of US$ 421, revenue growth forecast of 55.7%, and profit growth estimate of 145.6% for FY25, based on top 31 analyst calls.